Novo Nordisk (NVO) Shares Up Since Jim Cramer Said He Was A Buyer

Novo Nordisk A/S (NYSE:NVO) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks.

Novo Nordisk A/S (NYSE:NVO) is a key player in the weight loss drug industry. The firm made a splash earlier this year when it became the first to secure the FDA’s approval for a weight loss drug pill. With the announcement occurring on December 22nd, Novo Nordisk A/S (NYSE:NVO)’s shares closed 7.3% higher on the 23rd. Since Cramer discussed the firm in April 2025, the shares are up by 44%, while they are down by 48% over the year. 2026 hasn’t been a great year for Novo Nordisk A/S (NYSE:NVO)’s shares either, as they are down by 31% year-to-date. On February 23rd, the shares closed 16.4% lower as the firm reported that its next-generation weight loss drug, CagriSema, failed to match rival Eli Lilly’s offering. The announcement marked another day of weak performance, as Novo Nordisk A/S (NYSE:NVO)’s stock had dipped by 19% between February 2nd and February 4th after the pharma company surprised investors through its guidance and commented that revenue and operating profit could dip between 5% and 13% each in 2026. Here’s what Cramer said about the firm on Mad Money:

“I do…. It got low enough. When it hit 3.6% yield, it was low enough. Apparently, they’re doing exactly what President Trump wants. I am a buyer at this point in Novo Nordisk, though of course I do like Eli Lilly more, but this stock has come down enough.”

Jirsak/Shutterstock.com

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.